Log in

NASDAQ:TYMETyme Technologies Stock Price, Forecast & News

$1.19
-0.03 (-2.46 %)
(As of 07/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.15
Now: $1.19
$1.23
50-Day Range
$1.19
MA: $1.39
$1.59
52-Week Range
$0.86
Now: $1.19
$2.04
Volume414,000 shs
Average Volume442,319 shs
Market Capitalization$146.18 million
P/E RatioN/A
Dividend YieldN/A
Beta0.97
Tyme Technologies, Inc., a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
Read More
Tyme Technologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.31 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TYME
CUSIPN/A
Phone212-461-2315

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.15 per share

Profitability

Net Income$-22,000,000.00

Miscellaneous

Employees11
Market Cap$146.18 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive TYME News and Ratings via Email

Sign-up to receive the latest news and ratings for TYME and its competitors with MarketBeat's FREE daily newsletter.

Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions

How has Tyme Technologies' stock been impacted by COVID-19 (Coronavirus)?

Tyme Technologies' stock was trading at $1.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TYME stock has increased by 13.3% and is now trading at $1.19. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Tyme Technologies?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tyme Technologies.

When is Tyme Technologies' next earnings date?

Tyme Technologies is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Tyme Technologies.

How were Tyme Technologies' earnings last quarter?

Tyme Technologies Inc (NASDAQ:TYME) announced its earnings results on Wednesday, May, 20th. The company reported ($0.04) EPS for the quarter, beating the Zacks' consensus estimate of ($0.07) by $0.03. View Tyme Technologies' earnings history.

What price target have analysts set for TYME?

2 equities research analysts have issued 1 year target prices for Tyme Technologies' stock. Their forecasts range from $9.50 to $9.50. On average, they expect Tyme Technologies' stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 698.3% from the stock's current price. View analysts' price targets for Tyme Technologies.

Has Tyme Technologies been receiving favorable news coverage?

Media stories about TYME stock have trended extremely negative this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Tyme Technologies earned a coverage optimism score of -4.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an impact on the stock's share price in the next few days. View the latest news about Tyme Technologies.

Are investors shorting Tyme Technologies?

Tyme Technologies saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 4,090,000 shares, a decline of 8.1% from the June 15th total of 4,450,000 shares. Based on an average daily trading volume, of 369,400 shares, the short-interest ratio is presently 11.1 days. Currently, 7.5% of the shares of the company are sold short. View Tyme Technologies' Current Options Chain.

Who are some of Tyme Technologies' key competitors?

What other stocks do shareholders of Tyme Technologies own?

Who are Tyme Technologies' key executives?

Tyme Technologies' management team includes the following people:
  • Mr. Steven E. Hoffman, Co-Founder, Chairman, CEO & Chief Science Officer (Age 56)
  • Mr. Ben R. Taylor, Pres & CFO (Age 42)
  • Mr. Michael S. Demurjian, Co-Founder, Exec. VP, COO & Director (Age 52)
  • Mr. James Biehl J.D., Chief Legal Officer & Sec. (Age 55)
  • Dr. Giuseppe Del Priore, Chief Medical Officer (Age 57)

What is Tyme Technologies' stock symbol?

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

How do I buy shares of Tyme Technologies?

Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tyme Technologies' stock price today?

One share of TYME stock can currently be purchased for approximately $1.19.

How big of a company is Tyme Technologies?

Tyme Technologies has a market capitalization of $146.18 million. The company earns $-22,000,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. Tyme Technologies employs 11 workers across the globe.

What is Tyme Technologies' official website?

The official website for Tyme Technologies is www.tymeinc.com.

How can I contact Tyme Technologies?

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected]

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.